Fig. 4

BAM15 suppresses tumor growth in lean C57BL/6J mice. A Schematic illustration of the experimental design. B Tumor volumes over the treatment period and C terminal tumor mass (CTRL N=11, BAM15 N=12). D BAM15 concentrations in plasma (N=4) and tumor (N=8) 1 h after an acute gavage of 50 mg/kg of BAM15 at time of necropsy and plasma and tissue after ad libitum access to BAM15 diet (plasma, iWAT, and liver N=4, tumor N=6, and gastrocnemius N=3). E Proton leak and F ET capacity in tumors 1 h after an acute gavage of 50 mg/kg of BAM15 (N=4 per condition). G Total daily energy expenditure in mice over the last 7 days of treatment (CTRL N=8, BAM15 N=7). H Body weight over the treatment period and I change in body weight from treatment start (CTRL N=23 and BAM15 N=21). J Food intake averaged over the treatment period (CTRL N=21 and BAM15 N=22). K Terminal gWAT weight and L iWAT weight (CTRL N=9, BAM15 N=11). Data are shown as a box (mean ± 5–95% CI) and whiskers (minimum to maximum) except for B and H which are displayed as the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Panels B and H were assessed by two-way repeated measures ANOVA with Tukey’s multiple comparisons. Panels C, D, E, F, G, I, J, K, and L were assessed by one-way ANOVA with Tukey’s multiple comparisons. Panel H was assessed by extra sum-of-squares F test. Abbreviations: CTRL, control; TDEE, total daily energy expenditure; gWAT, gonadal white adipose tissue; iWAT, inguinal white adipose tissue; gastroc, gastrocnemius